Program

Scientific Program (preliminary)

← BACK


Day 1 – Thursday, October 8, 2026


13:00 Summit Welcome

1.1 Joint Preservation Updates

  • NITRO Program Updates
  • Moonshot cartilage repair/ DoD grant
  • First presentation of data from the Richardson / Keele Trial
  • IMPACT study
  • Discussion

1.2 Meniscus preservation strategies: the translational frontier

  • Meniscus engineering: The future
  • The degenerative meniscus: A challenging environment
  • Biomaterials for meniscus
  • Meniscectomy: Morphological profiling and predictive modeling
  • Discussion

1.3 From Bench to Business: Startup Spotlight

  • BiomimX
  • Terra Quantum
  • Vanarix

1.4 Meniscus preservation strategies: The clinical challenge

  • The Delphi consensus
  • Medial and lateral meniscus root repair – When?
  • Orthobiologic injectables and meniscus
  • Meniscus: The challenging management in athletes
  • Meniscus Discovery channel
  • Discussion

1.5 Next Gen Session – Career Mentoring

Welcome Reception

 

Day 2 – Friday, October 9, 2026


2.1 Portugal meets ICRS Joint Session 

  • Osteochondral tissue engineering and biofabricated in vitro 3D models
  • Mosaicplasty. Is this still an option in 2026?
  • Biomaterials / Tissue engineering
  • TBD
  • Discussion

2.2 Novel therapeutics for joint regeneration

  • Biomaterial Cell therapeutics
  • Allogenic Therapy
  • Organoids for Regenerative Medicine
  • IPSC Cells
  • Discussion

2.3 Poster session with coffee

2.4 Orthobiologics – The best injectable

  • HA – Eurovisco
  • Polynucleotides
  • PRP
  • Point of care: Bone Marrow vs Adipose tissue
  • What is the consensus? The ESSKA-ICRS consensus results
  • Discussion

2.5 Orthotinder: Osteochondral lesions

  • Osteochondral scaffolds: Aragonite-based
  • Osteochondral scaffolds: Collagen-based
  • Allografts
  • Personalized metal
  • Discussion

Lunch

2.6 Orthotinder: Cartilage regeneration

  • MACT
  • Chondral membranes
  • Minced cartilage
  • Umbilical cord stem cells
  • Discussion

2.7 Nextgen injectables: Should we abandon cells and go with vesicles or mitochondria?

  • Rationale for Mitochondrial TTX
  • Mitochondria TTX for OA
  • Mitochondria for Cartilage Repair
  • EV’s for joint homeostasis
  • Discussion

2.8 Cartilage Repair in Other Parts of the World

  • Asia
  • Europe
  • USA
  • South America
  • Discussion

Updates from the ICRS patient registry

2.9 ICRS and Friends

  • AtiO meets ICRS – Clinically relevant biomechanical parameters for cartilage repair
  • BA meets ICRS – BARB updates
  • ISAKOS meets ICRS – Joint consensus projects
  • Discussion

Faculty Dinner

 

Day 3 – Saturday, October 10, 2026


3.1 Beyond the Knee: Cartilage Preservation in Other Joints

  • IVD
  • Ankle Joint
  • Shoulder
  • Hip
  • Discussion

3.2 Gene therapy: Bench to Bedside

  • Phase 3 Clinical trial of Kolon – TissueGene
  • Gene therapy for OA and Cartilage repair
  • Gene therapy Clinical Trial
  • Discussion

3.3 A new player in the field

  • Weight losing drugs in OA/ GLP-1

3.4 Joint Preservation: beyond cartilage

  • How much can we push surgical indications? My most complex cases
  • Slow-release pain medicine
  • Optimizing Outcomes: The Role of Concomitant Surgeries in Cartilage Repair
  • Personalizing Cartilage Repair: Factors Beyond Defect Dimensions
  • COST NetwOArk
  • Discussion

3.5 Selected podium presentations awards

13:00 – Congress closing remarks: Daniel Grande